Drug intelligence / Profile preview

MTX-001 PRO

Development stage: Preclinical
Lead developer: Merakris Therapeutics
Modality: Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
Administration: Topical

Overview

MTX-001 PRO is a cell-free amniotic fluid liquid formulation developed by Merakris Therapeutics for wound care applications. As a liquid line expansion of the MTX-001 platform, it is designed for topical or local application to deliver a concentrated milieu of bioactive components, including exosomes, cytokines, chemokines, polysaccharides, and hyaluronic acid. These factors are intended to promote tissue repair and regeneration by modulating biological pathways such as the epithelial-mesenchymal transition (EMT). The product is currently in the preclinical stage of development, specifically targeting the expansion of the company's liquid wound care offerings.

Beyond the preview

Go deeper on MTX-001 PRO.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MTX-001 PRO.

Explore the full profile